ArticleCancer research2022
Dissecting the Oncogenic Roles of Keratin 17 in the Hallmarks of Cancer.
Article in Cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 39 citations in OpenAlex.
- Keratin 17 immunocytochemistry in urine cytology for urothelial carcinoma detection: Diagnostic performance and interobserver agreement in a prospective real-world cohort.Cancer cytopathology · 2026Article
- Data modeling the interplay between single-cell shape, single-cell protein expression, and tissue state.Cell reports methods · 2026Article
- Mitochondrial-Localized Keratin 17 Promotes Chemoresistance in Basal-like Pancreatic Cancer.Cancer research · 2026Article
- SpaceBF: spatial coexpression analysis using Bayesian fused approaches in spatial omics datasets.GigaScience · 2026Article
- Low tumoral Trefoil Factor 1 expression relates to aggressive tumor features and poor survival in young women with breast cancer.Scientific reports · 2026Article
- Identification of a Prognostic Gene Signature Based on Lenvatinib Resistance in Hepatocellular Carcinoma with Functional Validation of the Key Gene CPB2.Journal of hepatocellular carcinoma · 2026Article
- Structure and function of the keratin 17 tail domain associated with keratin intermediate filament organization.European journal of cell biology · 2025Article
- MCPIP3/Regnase-3 binds 14-3-3 proteins and contributes to the regulation of the cell cycle in human immortalized keratinocytes.Scientific reports · 2025Article
- Review
- Multimodal fusion strategies for survival prediction in breast cancer: A comparative deep learning study.Computational and structural biotechnology journal · 2025Article
- KRT17: A Key Driver of Cancer Therapy Resistance and Emerging Therapeutic Target.Cancer management and research · 2025Review
- The Intersection of Psoriasis and Neoplasia: Risk Factors, Therapeutic Approaches, and Management Strategies.Cancers · 2024Review
- Mucosa-like differentiation of head and neck cancer cells is inducible and drives the epigenetic loss of cell malignancy.Cell death & disease · 2024Article
- Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma.American journal of clinical pathology · 2024Article
- Keratins 6, 16, and 17 in Health and Disease: A Summary of Recent Findings.Current issues in molecular biology · 2024Review
- Repeated stress to the skin amplifies neutrophil infiltration in a keratin 17- and PKCα-dependent manner.PLoS biology · 2024Article
- Unraveling the Keratin Expression in Oral Leukoplakia: A Scoping Review.International journal of molecular sciences · 2024Article
- Keratin 17 modulates the immune topography of pancreatic cancer.Journal of translational medicine · 2024Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
There is an unmet need to identify and validate tumor-specific therapeutic targets to enable more effective treatments for cancer. Heterogeneity in patient clinical characteristics as well as biological and genetic features of tumors present major challenges for the optimization of therapeutic interventions, including the development of novel and more effective precision medicine. The expression of keratin 17 (K17) is a hallmark of the most aggressive forms of cancer across a wide range of anatomical sites and histological types. K17 correlates with shorter patient survival, predicts resistance to specific chemotherapeutic agents, and harbors functional domains that suggest it could be therapeutically targeted. Here, we explore the role of K17 in the hallmarks of cancer and summarize evidence to date for K17-mediated mechanisms involved in each hallmark, elucidating functional roles that warrant further investigation to guide the development of novel therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.